Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Zydus Cadila registers Total income from Operations of Rs. 3367 Cr, up 14% in Q2

Posted On: 2019-11-13 21:01:50

For the second quarter ended September 30, 2019, Zydus Cadila reported total income from operations of Rs. 3367 cr., up by 14% on a y-o-y basis. Earnings before Interest, Depreciation and Tax (EBIDTA) for the quarter was Rs. 626 cr, while the Net profit for the quarter stood at Rs. 107 cr. which includes an impairment charge of Rs. 268 cr. towards Levorphanol intangibles on account of entry of a new competitor. Adjusted for this, the Profit After Tax for the quarter stood at Rs. 319 cr.

The company's India business which comprises human formulations, consumer wellness and animal health business posted sales of Rs.1430 cr., up by 24% en a y-o-y basis. The company's business in the US posted sales of Rs. 1450 cr., up by 10% on a y-o-y basis. During the quarter, the company launched 7 new products in the US. The company filed 8 additional ANDAS with the USFDA and received 6 ANDA approvals, during the quarter. The company's business in the emerging markets of Asia, Africa and Latin America grew by 8%.

Making progress in its research programme, during the quarter, the company completed EVIDENCES IV Phase II clinical trials of Saroglitazar Magnesium in patients with Non Aieoholic Fatty Liver Disease (NAFLD) and an-Alcoholic Steatehepatitis (NASH) as the molecule achieved the primary efficacy eud-points. A statistically significant 44.39% reduction in ALT (alanine aminotransferase) was observed in patients treated with Saroglitazar Magnesium. The EVIDENCES [V NASH trial was a randomized, double-blind, placebo-controlled study that enrolled 106 patients with NAFLD, including NASH across 20 clinical sites in the United States of America.

A presentation on Saroglitazar in NAFLD was presented at AASLD 2019 held at Boston which highlighted the statistical significance of Saroglitazar when compared to the placebo in primary endpoint. This paper was selected as one of the best NAFLD/NASH debriefs presented at the AASLD Conference.

The Company also initiated patient enrolment for EVIDENCES VII Phase II clinical trials for evaluating the effect of Saroglitazar Magnesium in the treatment of NAFLD in women with polycystic ovary syndrome (PCOS) during the quarter. The patients are being recruited across multiple clinical sites in the US and Mexico.

Making progress with its vaccine research programme, the Company received the marketing authorization in India from the DCGl for Measles and Rubella vaccine during the quarter. The Phase II / III clinical trials for Pentavalent Vaccine were also completed and the Company received regulatory approval to initiate Phase I clinical trials for Recombinant Hepatitis B Vaccine. In a major breakthrough, the Company received the marketing authorization for TwinrabTM (RabiMabs) from the Drug Controller General oflndia. The novel biologic which is a first-of-its-kind next gen therapy, is indicated in combination with rabies vaccine for rabies post-exposure prophylaxis. The United States Food and Drug Administration (USFDA) has granted an orphan drug status to this candidate.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.224.65 as compared to the previous close of Rs. 230.25. The total number of shares traded during the day was 106808 in over 1762 trades.

The stock hit an intraday high of Rs. 232.6 and intraday low of 223.6. The net turnover during the day was Rs. 24256998.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Bank of India board approves fund raising through issue of upto 125 crore shares

Ind-Ra affirms JK Paper's long-term issuer rating

Security and Intelligence Services India Ltd to acquire 51% in Adis Enterprises Pvt Ltd

ITC Ltd acquires stake in Delectable Technologies Pvt. Ltd.

Dynacons recognized as part of the Deloitte Technology Fast 50 India 2019

TCS' Advanced Drug Development Suite wins the India Pharma Award 2019

Zensar Partners with Education Africa to support students of Business Management

Fire at Oriental Aromatics Ltd's catalyst plant

Mitsu Chem Plast Ltd Board to consider Bonus Issue

Shri Jairam Sridharan, CFO of AXIS Bank resigns

Carnation Industries Ltd shuts plant for maintenance, repays dues to SBI, PNB

Issue of US$ 500 Million 3.50 Per Cent Notes By REC Limited

Vascon Engineers Ltd receives Rs. 132.69 crores work order from AAI

KEC International wins New Orders of Rs. 1,025 crore

RBI imposes penalty of Rs. 25 lakh on Andhra Bank

JSW Steel Ltd to seek clarifications on NCLAT order

G Bank, Myanmar Selects Infosys Finacle to Power its Growth

Thomas Cook India's Regional Maharashtra Tours witness a surge in demand of 27% from the State

Maruti Suzuki to proactively recall 63,493 Petrol Smart Hybrid variants of Ciaz, Ertiga and XL6 models

Dr. Reddy's Laboratories announces the launch of D.eferasirox Tablets for Oral Suspension, in the U.S. Market

Granules India Ltd clarifies on presence of NDMA in Metformin manufactured by the company

Bajaj Finance participates in QIP of RBL Bank Ltd

Cadila Healthcare Ltd receives EIR for API facility at Dabhasa, Gujarat

RBL Bank successfully closes QIP, raises Rs. 2,025 Crore

CARE revises ratings of Shakti Pumps India Ltd

Aite Group Names Majesco the Top 'Best-inClass' Vendor in the P&C Policy Administration Aite Matrix Report

Liberty Mutual Enhances Commercial Insurance Underwriting through Mastery of Big Data, adding more value to Brokers and Buyers

Shortlisted ideas from the European Tour Innovation Hub with Tata Communications show how latest digital technologies could revolutionise golf

Mercator Ltd board approves sale of PI in oil block

Pennar Industries bags orders worth INR 302 Crore

ICRA assigns credit ratings to NELCAST Ltd

Affle launches Vizury Engage360 to simplify omnichannel marketing

CARE A+ rating of Equitas Small Finance Bank Ltd reaffirmed

Reliance Power Ltd updates on rating action by Ind-RA

Moody's downgrades Yes Bank's ratings, assigns negative outlook

CARE reaffirms rating of NACL Industries Limited

Narayana Hrudayalaya announces discontinuation of Hospital Project in Kenya

Renascent Power acquires 75.01% stake in Prayagraj Power Generation Company Ltd

Sadbhav Tumkur Highway Private Ltd signs termination of concession agreement with NHAI

Nirlon Ltd, J.P. Morgan Sign Real Estate Transaction in Mumbai

Gati launches itself into the next phase of growth with All Cargo Logistics & Kintetsu World Express, Japan

Grant of second patent to Dr. Ashish Rawandale Patil, MD of Tejnaksh Healthcare Ltd for the 5 Part Access Needle

PBM Polytex Ltd updates on stoppage of production at Borgaon unit

Bank of Baroda approves raising of bonds upto Rs. 1850 crore

AnSem, a Cyient Company, Joins the Arm Approved Design Partner Program

Carnation Industries Limited enters into sale agreement for Uluberia Unit

URJA Global Ltd to participate in EV-EXPO

DCM Shriram Ltd commissions 200 KLD Distillery at Ajbapur

Brickwork Ratings downgrades rating of Vodafone Idea Limited's NCDs

JSW Steel gets favorable verdict from NCLAT on its appeal







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019